|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
77,230,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. AT-007 is a central nervous system penetrant ARI that Co. is developing for the treatment of metabolic diseases, including Galactosemia, a pediatric metabolic disease that affects how the body processes a simple sugar called galactose. AT-001 is an ARI with systemic exposure and peripheral nerve permeability that Co. is developing for the treatment of diabetic cardiomyopathy. AT-003 is an ARI designed to cross through the back of the eye when dosed orally for the treatment of diabetic retinopathy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
30,000 |
3,691,409 |
Total Buy Value |
$0 |
$0 |
$65,367 |
$3,658,451 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
1 |
5 |
Total Shares Sold |
506,975 |
506,975 |
1,224,775 |
1,251,193 |
Total Sell Value |
$2,732,596 |
$2,732,596 |
$4,466,825 |
$4,490,865 |
Total People Sold |
4 |
4 |
6 |
6 |
Total Sell Transactions |
4 |
4 |
14 |
17 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hooks Corwin Dale |
Chief Commercial Officer |
|
2024-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
Perfetti Riccardo |
Chief Medical Officer |
|
2024-03-14 |
4 |
S |
$5.39 |
$597,234 |
D/D |
(110,804) |
1,031,537 |
|
- |
|
Funtleyder Leslie D. |
Chief Financial Officer |
|
2024-03-14 |
4 |
S |
$5.39 |
$154,839 |
D/D |
(28,727) |
308,421 |
|
- |
|
Hansard Adam |
Chief Commercial Officer |
|
2024-03-14 |
4 |
S |
$5.39 |
$263,415 |
D/D |
(48,871) |
732,919 |
|
- |
|
Shendelman Shoshana |
President and CEO |
|
2024-03-14 |
4 |
S |
$5.39 |
$1,717,108 |
D/D |
(318,573) |
3,817,814 |
|
- |
|
Chinoporos Constantine |
See Remarks |
|
2023-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
Hansard Adam |
Chief Commercial Officer |
|
2023-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
781,790 |
|
- |
|
Shendelman Shoshana |
President and CEO |
|
2023-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,540,000 |
4,136,387 |
|
- |
|
Perfetti Riccardo |
Chief Medical Officer |
|
2023-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
450,000 |
1,142,341 |
|
- |
|
Kanter Stacy J. |
Director |
|
2023-12-01 |
4 |
B |
$2.18 |
$65,367 |
D/D |
30,000 |
63,000 |
2.39 |
- |
|
Perfetti Riccardo |
Chief Medical Officer |
|
2023-11-30 |
4 |
S |
$1.97 |
$3,119 |
D/D |
(1,583) |
692,341 |
|
- |
|
Hansard Adam |
Chief Commercial Officer |
|
2023-11-30 |
4 |
S |
$1.97 |
$1,901 |
D/D |
(965) |
381,790 |
|
- |
|
Shendelman Shoshana |
President and CEO |
|
2023-11-30 |
4 |
S |
$1.97 |
$7,817 |
D/D |
(3,968) |
2,596,387 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2023-11-29 |
4 |
D |
$0.00 |
$0 |
I/I |
(575,000) |
203,977 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2023-11-29 |
4 |
A |
$0.00 |
$0 |
I/I |
575,000 |
6,155,077 |
|
- |
|
Funtleyder Leslie D. |
Chief Financial Officer |
|
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
337,148 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2023-11-03 |
4 |
S |
$2.31 |
$331,370 |
I/I |
(143,450) |
5,580,077 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2023-11-02 |
4 |
S |
$2.32 |
$240,835 |
I/I |
(103,808) |
5,723,527 |
|
- |
|
Alexandria Equities No. 7, Llc |
10% Owner |
|
2023-11-01 |
4 |
S |
$2.36 |
$407,671 |
I/I |
(172,742) |
5,827,335 |
|
- |
|
Alexandria Equities No. 7, Llc |
10% Owner |
|
2023-10-31 |
4 |
S |
$2.41 |
$373,550 |
I/I |
(155,000) |
6,000,077 |
|
- |
|
Alexandria Equities No. 7, Llc |
10% Owner |
|
2023-10-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,600,000) |
778,977 |
|
- |
|
Alexandria Equities No. 7, Llc |
10% Owner |
|
2023-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,600,000 |
6,155,077 |
|
- |
|
Shendelman Shoshana |
President and CEO |
|
2023-09-27 |
4 |
S |
$2.70 |
$312,206 |
D/D |
(115,632) |
2,600,355 |
|
- |
|
Hansard Adam |
Chief Commercial Officer |
|
2023-09-27 |
4 |
S |
$2.70 |
$26,244 |
D/D |
(9,720) |
382,755 |
|
- |
|
Perfetti Riccardo |
Chief Medical Officer |
|
2023-09-27 |
4 |
S |
$2.70 |
$29,516 |
D/D |
(10,932) |
693,924 |
|
- |
|
243 Records found
|
|
Page 1 of 10 |
|
|